查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830883

2025年全球放射性配體療法市場報告

Radioligand Therapy Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，放射性配體療法市場發展迅速，預計從2024年的60.1億美元成長到2025年的66.4億美元，複合年成長率達10.5%。預測期內的成長主要歸功於液態切片的日益普及、腫瘤診斷療法的出現、人工智慧在腫瘤學領域的應用、雙特異性抗體研發管線的不斷擴大以及政府對癌症研究投入的增加。

預計未來幾年放射性配體療法市場將快速成長，到2029年市場規模將達到97.7億美元，複合年成長率（CAGR）為10.2%。推動預測期內市場成長的因素包括：大型製藥企業加大對腫瘤新興企業的投資、更多地利用真實世界證據、放射性藥物和治療診斷學領域的研究不斷拓展、產學研合作日益加強，以及罕見疾病和孤兒癌發病率不斷上升。這段時期的主要發展趨勢包括：基於人工智慧的放射性藥物設計、結合成像和治療平台的診療治療診斷學、基於微流體的放射性示踪劑合成、下一代α發射同位素的開發以及3D列印的個人化劑量測定設備。

放射性配體療法（RLT）是一種先進的標靶癌症治療方法，它將放射性同位素連接到專門設計的配體上，該配體能夠與癌細胞上的受體結合。 RLT 給藥後，可針對癌細胞，將精確的輻射直接輸送到癌細胞，同時最大限度地減少對健康組織的損傷。這種標靶機制可以減少副作用並提高治療效果，尤其適用於對傳統治療方法抗藥性的病例。

放射性配體療法（RLT）中使用的主要放射性配體包括α粒子發射體、BETA粒子發射體、俄歇粒子發射體和複合粒子發射體。 α粒子發射體可在極短距離內（通常僅穿透幾個細胞層）發射高能量α粒子，因此能夠高效地精確破壞細胞。這些放射性配體分子標靶，例如荷爾蒙受體、生長因子受體和腫瘤抗原標記。給藥途徑多種多樣，包括靜脈注射。放射性配體療法用於治療多種疾病，包括癌症、心血管疾病、神經系統疾病和感染疾病，並廣泛應用於醫院、診斷實驗室、研究機構和居家醫療機構。

2025年，美國關稅的突然上漲及其引發的貿易摩擦對製藥公司造成了嚴重衝擊，這些公司正努力應對原料藥、玻璃瓶和實驗室設備等產品的關稅問題。利潤率高的學名藥生產商尤其脆弱，一些公司不得不縮減低利潤藥物的生產規模。生物技術公司也因關稅導致的特種試劑短缺而面臨臨床試驗延期的困境。為了應對這一局面，製藥業正在印度和歐洲擴大原料藥的生產，增加庫存，並遊說政府對基本藥物給予貿易豁免。

本研究報告是商業研究公司（The Business Research Company）最新系列報告的一部分，提供放射性配體療法市場統計數據，包括全球市場規模、區域佔有率、競爭對手及其市場佔有率、詳細的市場細分、市場趨勢以及放射性配體療法行業的商機，為您提供在該行業取得成功所需的關鍵數據。本市場研究報告對該行業的現狀和未來發展趨勢進行了深入分析，為您提供全面的觀點。

預計未來幾年，癌症發生率的上升將推動放射性配體療法市場的成長。癌症的特徵是異常細胞不受控制地增殖，侵入周圍組織並擴散至全身。癌症患者數量的增加與長期暴露於環境污染物密切相關，這些污染物會損傷DNA、破壞細胞功能並促進異常細胞生長。放射性配體療法透過配體與特定受體結合，利用輻射靶向癌細胞，從內部破壞癌細胞，同時最大限度地減少對健康組織的損傷。例如，根據美國癌症協會（美國非營利組織）預測，2022年1月美國預計將新增約190萬例癌症病例和609,360例癌症相關死亡病例，相當於每天約有1,670人死亡。因此，癌症盛行率的上升推動了放射性配體療法市場的擴張。

放射性配體療法市場的企業正日益重視開發先進的生產設施，以提高生產效率，同時確保標靶癌症治療藥物在生產和分銷過程中始終保持品質和安全標準。放射性配體療法生產設施是專門用於處理和交付靶向癌症治療放射性藥物的中心，配備先進的成像系統和輻射屏蔽設備、訓練有素的人員以及嚴格的安全通訊協定。例如，總部位於瑞士的製藥公司諾華公司於2024年1月宣布，其位於印第安納州的新型大型放射性配體療法（RLT）生產工廠已實現自動化，並獲得美國食品藥物管理局（FDA）的商業化生產批准。這座佔地7萬平方英尺的工廠是諾華公司規模最大、技術最先進的RLT專用生產設施，配備了全自動生產線，旨在高效、及時地生產，以滿足美國和加拿大日益成長的患者需求。

2023年12月，美國製藥公司禮來（Eli Lilly and Company）以14億美元收購了POINT Biopharma Global Inc.。此次收購增強了禮來在腫瘤領域的實力，並整合了先進的放射性配體療法技術，從而提升了精準癌症治療方案的選擇範圍。 POINT Biopharma Global Inc.同樣總部位於美國，專注於開發用於癌症治療的放射性配體療法。

放射性配體治療市場由提供標靶治療服務、診斷影像服務以及臨床和基礎設施服務等服務的營業單位所獲得的收入所構成。市場價值還包括服務提供者銷售的或包含在其服務產品中的相關產品的價值。放射性配體治療市場還包括生長抑制素受體配體、放射性標記的鈴蟾肽類似物、放射性標記的單株抗體以及前列腺特異性膜抗原 (PSMA) 靶向配體的銷售。該市場的價值為“出廠價”，即產品製造商或創造者銷售的產品價值，無論銷售對像是其他營業單位（包括下游製造商、批發商、經銷商和零售商）還是直接銷售給最終客戶。該市場的產品價值還包括產品創造者提供的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅，以及新冠疫情及其復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球放射性配體療法：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 終端用戶產業分析
  • 全球放射性配體治療市場：成長率分析
  • 全球放射性配體療法市場表現：規模與成長，2019-2024年
  • 全球放射性配體療法市場預測：規模與成長，2024-2029年，2034年
  • 全球放射性配體療法：潛在市場規模 (TAM)

第6章 市場細分

  • 全球放射性配體療法市場按類型、性能和預測分類，2019-2024年、2024-2029年、2034年
  • 阿爾法發射體
  • BETA射線放射體
  • 俄歇輻射發射器
  • 複合散熱器
  • 全球放射性配體療法市場按分子標靶靶、性能和預測分類，2019-2024年、2024-2029年和2034年
  • 荷爾蒙受體
  • 生長因子受體
  • 抗原腫瘤標記
  • 其他
  • 全球放射性配體療法市場依給藥途徑、效能及預測分類，2019-2024年、2024-2029年、2034年
  • 靜脈注射（IV）
  • 肌肉內注射（IM）
  • 皮下
  • 口服
  • 全球放射性配體療法市場：依應用、效能和預測分類，2019-2024年、2024-2029年、2034年
  • 癌症
  • 心血管疾病
  • 神經系統疾病
  • 感染疾病
  • 全球放射性配體治療市場（依最終使用者、表現和預測分類，2019-2024年、2024-2029年、2034年）
  • 醫院
  • 診斷實驗室
  • 研究所
  • 居家醫療
  • 全球放射性配體治療市場：α發射體細分市場，按類型、性能和預測，2019-2024年、2024-2029年、2034年
  • 錒-225 (Ac-225)
  • 鐳-223（Ra-223）
  • 砹-211（At-211）
  • 鉍-213（Bi-213）
  • 全球放射性配體治療市場：BETA發射體細分市場，按類型、性能和預測，2019-2024年、2024-2029年、2034年
  • 鎦-177（Lu-177）
  • 碘-131 (I-131)
  • 釔-90 (Y-90)
  • 釤-153 (Sm-153)
  • 全球放射性配體治療市場：俄歇發射器細分市場，按類型、性能和預測（2019-2024年、2024-2029年、2034年）
  • 碘-125 (I-125)
  • 銦-111 (In-111)
  • 鎵-67（Ga-67）
  • 鉈-201 (Tl-201)
  • 全球放射性配體治療市場：多發射體細分市場，按類型、性能和預測，2019-2024年、2024-2029年、2034年
  • 鋱-161 (Tb-161)
  • 銅-67（Cu-67）
  • 錸-186 (Re-186)
  • 鉛-212 (Pb-212)

第7章 區域和國家分析

  • 全球放射性配體治療市場：依地區、績效及預測分類，2019-2024年、2024-2029年、2034年
  • 全球放射性配體治療市場：國家、績效及預測，2019-2024年、2024-2029年、2034年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 放射性配體療法市場：競爭格局
  • 放射性配體治療市場：公司概況
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
    • Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Curium LLC Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Eckert & Ziegler Strahlen-und Medizintechnik AG
  • Molecular Partners AG
  • Telix Pharmaceuticals
  • Nanobiotix SA
  • Mariana Oncology Inc.
  • Artios Pharma Limited
  • AdvanCell Pty Ltd.
  • Evergreen Theragnostics Inc.
  • Fusion Pharmaceuticals Inc.
  • RadioMedix Inc.
  • Ariceum Therapeutics GmbH
  • Radiopharm Theranostics Limited
  • Convergent Therapeutics Inc.
  • C-Ray Therapeutics Inc.
  • OncoSil Medical Ltd.

第32章 全球市場競爭基準化分析與儀錶板

第33章 重大併購

第34章 近期市場趨勢

第35章：高潛力市場國家、細分市場與策略

  • 2029年放射性配體療法市場：提供新機會的國家
  • 放射性配體治療市場展望 2029：新興細分市場機會
  • 放射性配體療法市場2029年：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章附錄

簡介目錄
Product Code: r37874

Radioligand therapy (RLT) is an advanced targeted cancer treatment that attaches a radioactive isotope to a ligand specifically designed to bind to cancer cell receptors. Once administered, it targets tumor cells and delivers precise radiation directly to them, minimizing damage to healthy tissues. This targeted mechanism helps reduce side effects and enhances treatment outcomes, particularly in cases resistant to conventional therapies.

The primary types of radioligands used in RLT include alpha emitters, beta emitters, Auger emitters, and combined emission radioligands. Alpha emitters release high-energy alpha particles over very short distances, typically a few cell layers, making them highly effective for precise cell destruction. These radioligands are engineered to bind to specific molecular targets, such as hormone receptors, growth factor receptors, tumor antigen markers, and others. They can be administered via multiple routes, including intravenous (IV), intramuscular (IM), subcutaneous, and oral. Radioligand therapy is applied in treating a variety of conditions, including oncological and cardiovascular disorders, neurological diseases, and infectious diseases, and is utilized across hospitals, diagnostic laboratories, research institutions, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The radioligand therapy market research report is one of a series of new reports from The Business Research Company that provides radioligand therapy market statistics, including the radioligand therapy industry global market size, regional shares, competitors with the radioligand therapy market share, detailed radioligand therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the Radioligand therapy industry. This radioligand therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.01 billion in 2024 to $6.64 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to the increasing use of liquid biopsies, the emergence of tumor-agnostic therapies, the integration of artificial intelligence in oncology, the expanding pipeline of bispecific antibodies, and the rise in government funding for cancer research.

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $9.77 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing investments by major pharmaceutical companies in oncology startups, greater utilization of real-world evidence, expansion of research in radiopharmaceuticals and theranostics, strengthened collaborations between academia and industry, and the rising prevalence of rare and orphan cancers. Key trends expected during this period include AI-driven design of radiopharmaceuticals, theranostics with combined imaging and therapy platforms, microfluidics-based radiotracer synthesis, development of next-generation alpha-emitting isotopes, and 3D-printed personalized dosimetry devices.

The rising incidence of cancer is expected to drive growth in the radioligand therapy market in the coming years. Cancer is characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread throughout the body. The increase in cancer cases is linked to long-term exposure to environmental pollutants that damage DNA, disrupt cellular function, and promote abnormal cell proliferation. Radioligand therapy addresses cancer by delivering targeted radiation to tumor cells via ligands that bind to specific receptors, minimizing damage to healthy tissues while destroying cancer cells internally. For example, in January 2022, the American Cancer Society, a U.S.-based non-profit organization, reported that approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were expected in the U.S., translating to roughly 1,670 deaths per day. Therefore, the growing prevalence of cancer is supporting the expansion of the radioligand therapy market.

Companies in the radioligand therapy market are increasingly focusing on the development of advanced facilities to improve production efficiency while ensuring consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. Radioligand therapy facilities are specialized centers equipped to handle and deliver radioactive drugs for targeted cancer therapy, employing advanced imaging systems and radiation shielding, along with trained personnel and strict safety protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana, which received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, featuring fully automated production lines designed for efficient, time-sensitive manufacturing to meet rising patient demand in the U.S. and Canada.

In December 2023, Eli Lilly and Company, a U.S.-based pharmaceutical firm, acquired POINT Biopharma Global Inc. for \$1.4 billion. This acquisition strengthens Eli Lilly's oncology portfolio by integrating advanced radioligand therapy capabilities to enhance precision cancer treatment options. POINT Biopharma Global Inc., also based in the U.S., specializes in the development of radioligand therapies for cancer.

Major players in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc., OncoSil Medical Ltd.

North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the radioligand therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radioligand Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on radioligand therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radioligand therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radioligand therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type Of Radioligand: Alpha Emitters; Beta Emitters; Auger Emitters; Combined Emissions
  • 2) By Molecular Target: Hormone Receptors; Growth Factor Receptors; Antigen Tumor Markers; Other Molecular Targets
  • 3) By Route Of Administration: Intravenous (IV); Intramuscular (IM); Subcutaneous; Oral
  • 4) By Application: Oncology; Cardiovascular Disorders; Neurological Disorders; Infectious Diseases
  • 5) By End-User: Hospitals; Diagnostic Laboratories; Research Institutions; Home Care Settings
  • Subsegments:
  • 1) By Alpha Emitters: Actinium-225 (Ac-225); Radium-223 (Ra-223); Astatine-211 (At-211); Bismuth-213 (Bi-213)
  • 2) By Beta Emitters: Lutetium-177 (Lu-177); Iodine-131 (I-131); Yttrium-90 (Y-90); Samarium-153 (Sm-153)
  • 3) By Auger Emitters: Iodine-125 (I-125); Indium-111 (In-111); Gallium-67 (Ga-67); Thallium-201 (Tl-201)
  • 4) By Combined Emissions: Terbium-161 (Tb-161); Copper-67 (Cu-67); Rhenium-186 (Re-186); Lead-212 (Pb-212)
  • Companies Mentioned: Bayer AG; Novartis AG; Eli Lilly and Company; Lantheus Holdings Inc.; Curium LLC; Eckert & Ziegler Strahlen- und Medizintechnik AG; Molecular Partners AG; Telix Pharmaceuticals; Nanobiotix S.A.; Mariana Oncology Inc.; Artios Pharma Limited; AdvanCell Pty Ltd.; Evergreen Theragnostics Inc.; Fusion Pharmaceuticals Inc.; RadioMedix Inc.; Ariceum Therapeutics GmbH; Radiopharm Theranostics Limited; Convergent Therapeutics Inc.; C-Ray Therapeutics Inc.; OncoSil Medical Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Radioligand Therapy Market Characteristics

3. Radioligand Therapy Market Trends And Strategies

4. Radioligand Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Radioligand Therapy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Radioligand Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Radioligand Therapy Market Growth Rate Analysis
  • 5.4. Global Radioligand Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Radioligand Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Radioligand Therapy Total Addressable Market (TAM)

6. Radioligand Therapy Market Segmentation

  • 6.1. Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alpha Emitters
  • Beta Emitters
  • Auger Emitters
  • Combined Emissions
  • 6.2. Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormone Receptors
  • Growth Factor Receptors
  • Antigen Tumor Markers
  • Other Molecular Targets
  • 6.3. Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous
  • Oral
  • 6.4. Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Cardiovascular Disorders
  • Neurological Disorders
  • Infectious Diseases
  • 6.5. Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions
  • Home Care Settings
  • 6.6. Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Actinium-225 (Ac-225)
  • Radium-223 (Ra-223)
  • Astatine-211 (At-211)
  • Bismuth-213 (Bi-213)
  • 6.7. Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lutetium-177 (Lu-177)
  • Iodine-131 (I-131)
  • Yttrium-90 (Y-90)
  • Samarium-153 (Sm-153)
  • 6.8. Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Iodine-125 (I-125)
  • Indium-111 (In-111)
  • Gallium-67 (Ga-67)
  • Thallium-201 (Tl-201)
  • 6.9. Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Terbium-161 (Tb-161)
  • Copper-67 (Cu-67)
  • Rhenium-186 (Re-186)
  • Lead-212 (Pb-212)

7. Radioligand Therapy Market Regional And Country Analysis

  • 7.1. Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Radioligand Therapy Market

  • 8.1. Asia-Pacific Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Radioligand Therapy Market

  • 9.1. China Radioligand Therapy Market Overview
  • 9.2. China Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Radioligand Therapy Market

  • 10.1. India Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Radioligand Therapy Market

  • 11.1. Japan Radioligand Therapy Market Overview
  • 11.2. Japan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Radioligand Therapy Market

  • 12.1. Australia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Radioligand Therapy Market

  • 13.1. Indonesia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Radioligand Therapy Market

  • 14.1. South Korea Radioligand Therapy Market Overview
  • 14.2. South Korea Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Radioligand Therapy Market

  • 15.1. Western Europe Radioligand Therapy Market Overview
  • 15.2. Western Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Radioligand Therapy Market

  • 16.1. UK Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Radioligand Therapy Market

  • 17.1. Germany Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Radioligand Therapy Market

  • 18.1. France Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Radioligand Therapy Market

  • 19.1. Italy Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Radioligand Therapy Market

  • 20.1. Spain Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Radioligand Therapy Market

  • 21.1. Eastern Europe Radioligand Therapy Market Overview
  • 21.2. Eastern Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Radioligand Therapy Market

  • 22.1. Russia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Radioligand Therapy Market

  • 23.1. North America Radioligand Therapy Market Overview
  • 23.2. North America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Radioligand Therapy Market

  • 24.1. USA Radioligand Therapy Market Overview
  • 24.2. USA Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Radioligand Therapy Market

  • 25.1. Canada Radioligand Therapy Market Overview
  • 25.2. Canada Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Radioligand Therapy Market

  • 26.1. South America Radioligand Therapy Market Overview
  • 26.2. South America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Radioligand Therapy Market

  • 27.1. Brazil Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Radioligand Therapy Market

  • 28.1. Middle East Radioligand Therapy Market Overview
  • 28.2. Middle East Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Radioligand Therapy Market

  • 29.1. Africa Radioligand Therapy Market Overview
  • 29.2. Africa Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Radioligand Therapy Market Competitive Landscape And Company Profiles

  • 30.1. Radioligand Therapy Market Competitive Landscape
  • 30.2. Radioligand Therapy Market Company Profiles
    • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Curium LLC Overview, Products and Services, Strategy and Financial Analysis

31. Radioligand Therapy Market Other Major And Innovative Companies

  • 31.1. Eckert & Ziegler Strahlen- und Medizintechnik AG
  • 31.2. Molecular Partners AG
  • 31.3. Telix Pharmaceuticals
  • 31.4. Nanobiotix S.A.
  • 31.5. Mariana Oncology Inc.
  • 31.6. Artios Pharma Limited
  • 31.7. AdvanCell Pty Ltd.
  • 31.8. Evergreen Theragnostics Inc.
  • 31.9. Fusion Pharmaceuticals Inc.
  • 31.10. RadioMedix Inc.
  • 31.11. Ariceum Therapeutics GmbH
  • 31.12. Radiopharm Theranostics Limited
  • 31.13. Convergent Therapeutics Inc.
  • 31.14. C-Ray Therapeutics Inc.
  • 31.15. OncoSil Medical Ltd.

32. Global Radioligand Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Radioligand Therapy Market

34. Recent Developments In The Radioligand Therapy Market

35. Radioligand Therapy Market High Potential Countries, Segments and Strategies

  • 35.1 Radioligand Therapy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Radioligand Therapy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Radioligand Therapy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer